Adenosine-induced Asystole during AVM Embolization: A Case Series

• Published in: Clinical neuroradiology (Munich) 2022-03, Vol.32 (1), p.39-48
• Main Authors: Hellstern, V., Bhogal, P., Aguilar Pérez, M., Alfter, M., Kemmling, A., Henkes, E., Ganslandt, O., Henkes, H.
• Format: Article
• Language: English
• Subjects: Adenosine; Adolescent; Adult; Aged; Child; Embolization, Therapeutic - adverse effects; Embolization, Therapeutic - methods; Female; Heart Arrest; Humans; Intracranial Arteriovenous Malformations - diagnostic imaging; Intracranial Arteriovenous Malformations - therapy; Medicine; Medicine & Public Health; Middle Aged; Neurology; Neuroradiology; Neurosurgery; Original; Original Article; Retrospective Studies; Treatment Outcome; Young Adult
• ISSN: 1869-1439; 1869-1447
• DOI: 10.1007/s00062-021-01035-z

Background Adenosine induced cardiac standstill has been used intraoperatively for both aneurysm and arteriovenous malformation (AVM) surgery and embolization. We sought to report the results of adenosine induced cardiac standstill as an adjunct to endovascular embolization of brain AVMs. Material and Methods We retrospectively identified patients in our prospectively maintained database to identify all patients since January 2007 in whom adenosine was used to induce cardiac standstill during the embolization of a brain AVM. We recorded demographic data, clinical presentation, Spetzler Martin grade, rupture status, therapeutic intervention and number of embolization sessions, angiographic and clinical results, clinical and radiological outcomes and follow-up information. Results We identified 47 patients (22 female, 47%) with average age 42 ± 17 years (range 6–77 years) who had undergone AVM embolization procedures using adjunctive circulatory standstill with adenosine. In total there were 4 Spetzler Martin grade 1 (9%), 9 grade 2 (18%), 15 grade 3 (32%), 8 grade 4 (18%), and 11 grade 5 (23%) lesions. Of the AVMs six were ruptured or had previously ruptured. The average number of embolization procedures per patient was 5.7 ± 7.6 (range 1–37) with an average of 2.6 ± 2.2 (range 1–14) embolization procedures using adenosine. Overall morbidity was 17% ( n  = 8/47) and mortality 2.1% ( n  = 1/47), with permanent morbidity seen in 10.6% ( n  = 5/47) postembolization. Angiographic follow-up was available for 32 patients with no residual shunt seen in 26 (81%) and residual shunts seen in 6 patients (19%). The angiographic follow-up is still pending in 14 patients. At last follow-up 93.5% of patients were mRS ≤2 ( n  = 43/46). Conclusion Adenosine induced cardiac standstill represents a viable treatment strategy in high flow AVMs or AV shunts that carries a low risk of mortality and permanent neurological deficits.